3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
12
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms, Castration-Resistant
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Metastatic Castration-resistant Prostate Cancer
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Cisplatin
3
Pemetrexed
2
Etoposide
2
pomalidomide
1
etoposide phosphate
1
enzalutamide
1
bemiparin
1
apalutamide
1
alvocidib
1
abiraterone
1
Radiation
1
RRx-001
1
Gemcitabine
1
GSK2879552
1
Depsipeptides
1
Carboplatin
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Small Cell
×
abiraterone
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts